for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aspira Women's Health Inc

AWH.N

Latest Trade

6.71USD

Change

0.07(+1.05%)

Volume

15,580

Today's Range

5.62

 - 

6.72

52 Week Range

0.62

 - 

10.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.64
Open
6.58
Volume
15,580
3M AVG Volume
16.78
Today's High
6.72
Today's Low
5.62
52 Week High
10.47
52 Week Low
0.62
Shares Out (MIL)
111.56
Market Cap (MIL)
749.13
Forward P/E
-41.97
Dividend (Yield %)
--

Next Event

Vermillion Inc Annual Shareholders Meeting

Latest Developments

More

Aspira Women’s Health Inc Announces Pricing Of $45 Million Public Offering Of Common Stock

Aspira Women's Health Inc. Announces Proposed Public Offering Of Common Stock

Aspira Women's Health Inc Files For Mixed Shelf Of Upto $100 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aspira Women's Health Inc

Aspira Women’s Health Inc., formerly Vermillion, Inc., is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1, Overa and OVA1PLUS risk of malignancy tests for ovarian cancer. The Company also sells a product for genetic testing for specific women’s health diseases, called ASPiRA GenetiX, with a core focus on ovarian cancer. OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor before planned surgery. The Overa is a second-generation biomarker panel intended to maintain its product’s sensitivity while improving specificity. OVA1PLUS is a service offering combining its OVA1 and Overa products, designed to enhance accuracy and reduce false elevations in the intermediate-risk area.

Industry

Biotechnology & Drugs

Contact Info

Suite 100

12117 Bee Caves Road Building Three

AUSTIN, TX

78738

United States

+1.512.5190400

http://www.vermillion.com

Executive Leadership

James T. LaFrance

Independent Chairman of the Board

Valerie Barber Palmieri

President, Chief Executive Officer, Director

Robert Harry Beechey

Chief Financial Officer

Sandra E. Brooks

Independent Director

Nancy G. Cocozza

Independent Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.200

2019

-0.180

2020(E)

-0.160
Price To Earnings (TTM)
--
Price To Sales (TTM)
165.99
Price To Book (MRQ)
48.02
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
14.80
LT Debt To Equity (MRQ)
11.53
Return on Investment (TTM)
-102.62
Return on Equity (TTM)
-80.49

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up